Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: Influenza
Interventions: High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 31,989 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 105
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 88 more

Conditions: Pneumococcal Infections, Pneumococcal Vaccines
Interventions: V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 1,720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 66
States / cities: Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more

Conditions: Meningitis, Meningococcemia
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 13 Years to 21 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 9
States / cities: Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 6 more

Conditions: Immune Response
Interventions: Flulaval, Fluvirin, Fluzone, Fluarix, Afluria; Biological
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: RSV Respiratory Syncytial Virus
Interventions: AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more

Conditions: HIV Infections
Interventions: HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Covid-19 Prevention
Interventions: Ad26.COV2.S, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,085 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Stanford, California • Torrance, California • Iowa City, Iowa + 7 more

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Malaria,Falciparum
Interventions: 5 microgram VLPM01, 15 microgram VLPM01, 30 microgram VLPM01, Plasmodium falciparum challenge; Biological · Other
Lead sponsor: VLP Therapeutics; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,048 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 25
States / cities: Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more

Conditions: Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,098 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more

Conditions: Healthy Subjects
Interventions: 13 valent pneumococcal conjugate vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 18 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 36
States / cities: Benton, Arkansas • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more

Conditions: Staphylococcal Infections, Yeast Infections, Candidiasis
Interventions: NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM, NDV-3 vaccine without alum ID; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hepatitis B
Interventions: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 40 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more

Conditions: Meningococcal Infection
Interventions: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Swiftwater, Pennsylvania

Conditions: Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions: Gardasil, Survey; Biological · Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 26 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 2 Years to 9 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 35
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 31 more

Conditions: Diphtheria, Polio, Pertussis
Interventions: DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 36
States / cities: Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more

Conditions: Influenza
Interventions: Influenza virus vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Genital Herpes Simplex Type 2
Interventions: GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg); Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more

Conditions: Alzheimer Disease, Preclinical Alzheimer's Disease
Interventions: AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo; Biological · Other
Lead sponsor: Institute for Molecular Medicine; Other
Eligibility: 65 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Boca Raton, Florida • Miami Lakes, Florida • Stuart, Florida + 3 more

Conditions: Influenza Immunisation, Healthy Volunteers
Interventions: Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more

Search by objective public record fields.

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Immune Responses Induced by Different Licensed Influenza Vaccines

A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

A Study of Ad26.COV2.S in Adults (COVID-19)

Comparison of Delivery Routes of Flu Vaccine in Adults

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Safety and Immune Response of Different Pediatric Combination Vaccines.

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects